Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans

Core Insights - Lexicon Pharmaceuticals is set to present data from three studies on sotagliflozin, a dual SGLT 1 and 2 inhibitor, at upcoming medical meetings, including the American Heart Association's Scientific Sessions 2025 and the Hypertrophic Cardiomyopathy Society Scientific Sessions [1][2] Group 1: Sotagliflozin Overview - Sotagliflozin is an oral inhibitor targeting sodium-glucose cotransporter types 1 and 2 (SGLT1 and SGLT2), which are involved in glucose regulation [3] - The drug has been studied in approximately 20,000 patients across various conditions, including heart failure, diabetes, and chronic kidney disease, and is currently being investigated for hypertrophic cardiomyopathy (HCM) [3] Group 2: Upcoming Presentations - The first presentation will focus on the effects of dual SGLT1 and 2 inhibition on cardiac remodeling and diastolic dysfunction in mice with HCM, scheduled for November 7 [6] - The second presentation will discuss a randomized trial of sotagliflozin in heart failure with preserved ejection fraction (HFpEF) patients without diabetes, set for November 8 [6] - The third presentation will analyze major adverse cardiovascular events in individuals treated with sotagliflozin, also on November 8 [6] Group 3: Company Background - Lexicon Pharmaceuticals aims to pioneer transformative medicines through its Genome5000™ program, which has identified over 100 protein targets with therapeutic potential across various diseases [4] - The company has a pipeline of drug candidates in discovery and clinical development for conditions such as neuropathic pain, HCM, obesity, and metabolic disorders [4]